NBIX vs XENE
NBIX: Neurocrine is a profitably growing, neuroscience-focused biotech commercializing novel treatments for movement disorders, endocrine diseases, and psychiatric conditions with expanding late-stage pipeline and recent M&A. XENE: A pre-commercial neuroscience biotech racing to bring azetukalner, a differentiated potassium channel opener, through Phase 3 trials for epilepsy and depression.
Side-by-side fundamentals
| Metric | NBIX | XENE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $172.69 | $66.18 | |
| Market cap as of 2026-07-23 | $17.8B | $6.7B | |
| P/E as of 2026-07-23 | 26.70 | n/a | |
| PEG as of 2026-07-23 | 0.23 | -0.30 | XENE lower |
| Net margin as of 2026-07-23 | +21.6% | -867.3% | NBIX higher |
| Gross margin as of 2026-07-23 | +98.2% | n/a | |
| Operating margin as of 2026-07-23 | +25.4% | -969.8% | NBIX higher |
| ROE as of 2026-07-23 | +21.6% | -49.2% | NBIX higher |
| ROA as of 2026-07-23 | +15.1% | -46.4% | NBIX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +28.6% | -7.3% | NBIX higher |
| Revenue CAGR (3y) SEC XBRL | +24.3% | -77.8% | NBIX higher |
| Beta as of 2026-07-23 | 0.39 | 0.63 | |
| 1-year return as of 2026-07-22 close | +30.1% | +111.2% | XENE higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.